LT3302551T - Anksčiau negydyto metastazavusio her2 teigiamo krūties vėžio gydymo būdai - Google Patents
Anksčiau negydyto metastazavusio her2 teigiamo krūties vėžio gydymo būdaiInfo
- Publication number
- LT3302551T LT3302551T LTEPPCT/US2016/034835T LTUS2016034835T LT3302551T LT 3302551 T LT3302551 T LT 3302551T LT US2016034835 T LTUS2016034835 T LT US2016034835T LT 3302551 T LT3302551 T LT 3302551T
- Authority
- LT
- Lithuania
- Prior art keywords
- methods
- breast cancer
- metastatic breast
- previously untreated
- treating her2
- Prior art date
Links
- 206010055113 Breast cancer metastatic Diseases 0.000 title 1
- 101100314454 Caenorhabditis elegans tra-1 gene Proteins 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6855—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from breast cancer cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/68033—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a maytansine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Organic Chemistry (AREA)
- Cell Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562168809P | 2015-05-30 | 2015-05-30 | |
| PCT/US2016/034835 WO2016196373A2 (en) | 2015-05-30 | 2016-05-27 | Methods of treating her2-positive metastatic breast cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| LT3302551T true LT3302551T (lt) | 2024-09-10 |
Family
ID=56134616
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| LTEPPCT/US2016/034835T LT3302551T (lt) | 2015-05-30 | 2016-05-27 | Anksčiau negydyto metastazavusio her2 teigiamo krūties vėžio gydymo būdai |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US11406715B2 (lt) |
| EP (1) | EP3302551B1 (lt) |
| JP (3) | JP6822980B2 (lt) |
| CN (1) | CN107614015A (lt) |
| DK (1) | DK3302551T3 (lt) |
| FI (1) | FI3302551T3 (lt) |
| LT (1) | LT3302551T (lt) |
| PL (1) | PL3302551T3 (lt) |
| PT (1) | PT3302551T (lt) |
| RS (1) | RS65871B1 (lt) |
| WO (1) | WO2016196373A2 (lt) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018158716A1 (en) * | 2017-03-02 | 2018-09-07 | Cadila Healthcare Limited | Novel protein drug conjugate formulation |
| US20200114018A1 (en) * | 2018-10-15 | 2020-04-16 | Genentech, Inc. | Methods of treating residual breast cancer with trastuzumab emtansine |
| MA53933A (fr) * | 2018-10-21 | 2021-08-25 | Slsg Ltd Llc | Poly-immunothérapie pour le traitement du cancer du sein triple-négatif |
Family Cites Families (70)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4968603A (en) | 1986-12-31 | 1990-11-06 | The Regents Of The University Of California | Determination of status in neoplastic disease |
| WO1989006692A1 (en) | 1988-01-12 | 1989-07-27 | Genentech, Inc. | Method of treating tumor cells by inhibiting growth factor receptor function |
| US5720937A (en) | 1988-01-12 | 1998-02-24 | Genentech, Inc. | In vivo tumor detection assay |
| EP0474727B1 (en) | 1989-05-19 | 1997-07-23 | Genentech, Inc. | Her2 extracellular domain |
| US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
| WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
| US6800738B1 (en) | 1991-06-14 | 2004-10-05 | Genentech, Inc. | Method for making humanized antibodies |
| WO1992022653A1 (en) | 1991-06-14 | 1992-12-23 | Genentech, Inc. | Method for making humanized antibodies |
| US7018809B1 (en) | 1991-09-19 | 2006-03-28 | Genentech, Inc. | Expression of functional antibody fragments |
| US6267958B1 (en) | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
| US6685940B2 (en) | 1995-07-27 | 2004-02-03 | Genentech, Inc. | Protein formulation |
| US7371376B1 (en) | 1996-10-18 | 2008-05-13 | Genentech, Inc. | Anti-ErbB2 antibodies |
| EP0852951A1 (de) | 1996-11-19 | 1998-07-15 | Roche Diagnostics GmbH | Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern |
| DE69739673D1 (de) | 1996-11-27 | 2009-12-31 | Genentech Inc | Affinitätsreinigung von Polypeptid-Proteinen auf einer Protein A Matrix |
| ZA9811162B (en) | 1997-12-12 | 2000-06-07 | Genentech Inc | Treatment with anti-ERBB2 antibodies. |
| ATE398464T1 (de) | 1998-03-27 | 2008-07-15 | Genentech Inc | Synergie zwischen apo-2 ligand und antikörper gegen her-2 |
| WO1999057134A1 (en) | 1998-05-06 | 1999-11-11 | Genentech, Inc. | Protein purification by ion exchange chromatography |
| US6573043B1 (en) | 1998-10-07 | 2003-06-03 | Genentech, Inc. | Tissue analysis and kits therefor |
| SI1187632T1 (sl) | 1999-05-14 | 2009-04-30 | Genentech Inc | Zdravljenje z anti-ErbB2 protitelesi |
| DE60033658T2 (de) | 1999-06-25 | 2007-11-22 | Genentech, Inc., South San Francisco | Behandlung von prostata-krebs mit anti-erbb2 antikörpern |
| US20040013667A1 (en) | 1999-06-25 | 2004-01-22 | Genentech, Inc. | Treatment with anti-ErbB2 antibodies |
| US20030086924A1 (en) | 1999-06-25 | 2003-05-08 | Genentech, Inc. | Treatment with anti-ErbB2 antibodies |
| US7041292B1 (en) | 1999-06-25 | 2006-05-09 | Genentech, Inc. | Treating prostate cancer with anti-ErbB2 antibodies |
| US6949245B1 (en) | 1999-06-25 | 2005-09-27 | Genentech, Inc. | Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies |
| KR20110008112A (ko) | 1999-08-27 | 2011-01-25 | 제넨테크, 인크. | 항-ＥｒｂＢ2 항체 투여 치료 방법 |
| US6632979B2 (en) | 2000-03-16 | 2003-10-14 | Genentech, Inc. | Rodent HER2 tumor model |
| US7097840B2 (en) | 2000-03-16 | 2006-08-29 | Genentech, Inc. | Methods of treatment using anti-ErbB antibody-maytansinoid conjugates |
| CA2407556C (en) | 2000-05-19 | 2011-06-21 | Genentech, Inc. | Gene detection assay for improving the likelihood of an effective response to an erbb antagonist cancer therapy |
| US6984494B2 (en) | 2000-08-15 | 2006-01-10 | Genentech, Inc. | Analytical method |
| US6441163B1 (en) | 2001-05-31 | 2002-08-27 | Immunogen, Inc. | Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents |
| AU2003224916B2 (en) | 2002-04-10 | 2009-01-08 | Genentech, Inc. | Anti-HER2 antibody variants |
| ES2392525T3 (es) | 2002-07-15 | 2012-12-11 | F. Hoffmann-La Roche Ag | Tratamiento del cáncer con el anticuerpo dirigido contra ErbB2 rhuMAb 2C4 |
| LT1543038T (lt) | 2002-09-11 | 2017-07-10 | Genentech, Inc. | Baltymo gryninimas |
| CA2506320A1 (en) | 2002-11-21 | 2004-06-10 | Genentech, Inc. | Therapy of non-malignant diseases or disorders with anti-erbb2 antibodies |
| DK3095793T3 (da) | 2003-07-28 | 2020-05-25 | Genentech Inc | Reducering af udvaskning af protein A under en protein A-affinitetskromatografi |
| US7004206B2 (en) | 2004-01-29 | 2006-02-28 | Viken James P | Automatic fluid exchanger |
| US20060034840A1 (en) | 2004-04-08 | 2006-02-16 | Agus David B | ErbB antagonists for pain therapy |
| BRPI0510883B8 (pt) | 2004-06-01 | 2021-05-25 | Genentech Inc | composto conjugado de droga e anticorpo, composição farmacêutica, método de fabricação de composto conjugado de droga e anticorpo e usos de uma formulação, de um conjugado de droga e anticorpo e um agente quimioterapêutico e de uma combinação |
| GT200500155A (es) | 2004-06-16 | 2006-05-15 | Terapia del càncer resistente al platino | |
| KR20120068807A (ko) | 2004-07-22 | 2012-06-27 | 제넨테크, 인크. | Ｈｅｒ２ 항체 조성물 |
| JP2008510466A (ja) | 2004-08-19 | 2008-04-10 | ジェネンテック・インコーポレーテッド | エフェクター機能が変更しているポリペプチド変異体 |
| JO3000B1 (ar) | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
| ZA200704796B (en) | 2004-12-07 | 2008-11-26 | Genentech Inc | Selecting patients for therapy with a HER inhibitor |
| BRPI0518104B8 (pt) | 2005-01-21 | 2021-05-25 | Genentech Inc | artigo industrializado e uso de anticorpo her2 |
| UA95902C2 (ru) | 2005-02-23 | 2011-09-26 | Дженентек, Инк. | Способ увеличения времени развития заболевания или выживаемости у раковых пациентов |
| WO2006096861A2 (en) | 2005-03-08 | 2006-09-14 | Genentech, Inc. | METHODS FOR IDENTIFYING TUMORS RESPONSIVE TO TREATMENT WITH HER DIMERIZATION INHIBITORS (HDIs) |
| US20060212956A1 (en) | 2005-03-14 | 2006-09-21 | Genentech, Inc. | Animal model of ligand activated HER2 expressing tumors |
| JP2006316040A (ja) | 2005-05-13 | 2006-11-24 | Genentech Inc | Ｈｅｒｃｅｐｔｉｎ（登録商標）補助療法 |
| US20070009976A1 (en) | 2005-07-06 | 2007-01-11 | Helmut Lenz | Detection of a target antigen irrespective of the presence or absence of a corresponding therapeutic antibody |
| PE20070207A1 (es) | 2005-07-22 | 2007-03-09 | Genentech Inc | Tratamiento combinado de los tumores que expresan el her |
| US7700299B2 (en) | 2005-08-12 | 2010-04-20 | Hoffmann-La Roche Inc. | Method for predicting the response to a treatment |
| EP1934174B1 (en) | 2005-10-07 | 2011-04-06 | Exelixis, Inc. | Azetidines as mek inhibitors for the treatment of proliferative diseases |
| TW200812615A (en) | 2006-03-22 | 2008-03-16 | Hoffmann La Roche | Tumor therapy with an antibody for vascular endothelial growth factor and an antibody for human epithelial growth factor receptor type 2 |
| MX2008015581A (es) | 2006-06-05 | 2008-12-17 | Genentech Inc | Prolongacion de la supervivencia de pacientes con cancer con niveles elevados de egf o tgf-alfa. |
| MX2009001715A (es) | 2006-08-21 | 2009-02-25 | Hoffmann La Roche | Terapia tumoral con un anticuerpo anti-vegf. |
| WO2008031531A1 (en) | 2006-09-15 | 2008-03-20 | F. Hoffmann-La Roche Ag | Tumor therapy with a combination of anti-her2 antibodies |
| CA2677108A1 (en) | 2007-03-02 | 2008-09-12 | Genentech, Inc. | Predicting response to a her inhibitor |
| WO2008148546A2 (en) | 2007-06-06 | 2008-12-11 | F.Hoffmann-La Roche Ag | Composition of a first non-labeled monoclonal antibody binding to a tumor antigen and a non-cross reactive second monoclonal antibody labeled with a nir fluorescence label |
| EP2171090B1 (en) | 2007-06-08 | 2013-04-03 | Genentech, Inc. | Gene expression markers of tumor resistance to her2 inhibitor treatment |
| US9551033B2 (en) | 2007-06-08 | 2017-01-24 | Genentech, Inc. | Gene expression markers of tumor resistance to HER2 inhibitor treatment |
| ES2537352T3 (es) | 2007-09-12 | 2015-06-05 | Genentech, Inc. | Combinaciones de compuestos inhibidores de fosfoinositida 3-cinasa y agentes quimioterapéuticos, y metodos para su uso |
| KR20140015166A (ko) | 2007-10-30 | 2014-02-06 | 제넨테크, 인크. | 양이온 교환 크로마토그래피에 의한 항체 정제 |
| TWI472339B (zh) | 2008-01-30 | 2015-02-11 | Genentech Inc | 包含結合至ｈｅｒ２結構域ii之抗體及其酸性變異體的組合物 |
| TW200942552A (en) | 2008-03-06 | 2009-10-16 | Genentech Inc | Combination therapy with c-Met and HER antagonists |
| US8663643B2 (en) | 2008-03-18 | 2014-03-04 | Genentech, Inc. | Combinations of an anti-HER2 antibody-drug conjugate and chemotherapeutic agents, and methods of use |
| BRPI0812682A2 (pt) | 2008-06-16 | 2010-06-22 | Genentech Inc | tratamento de cáncer de mama metastático |
| WO2010136569A1 (en) | 2009-05-29 | 2010-12-02 | F. Hoffmann-La Roche Ag | Modulators for her2 signaling in her2 expressing patients with gastric cancer |
| US9345661B2 (en) | 2009-07-31 | 2016-05-24 | Genentech, Inc. | Subcutaneous anti-HER2 antibody formulations and uses thereof |
| TW201129380A (en) | 2009-12-04 | 2011-09-01 | Genentech Inc | Methods of treating metastatic breast cancer with trastuzumab-MCC-DM1 |
| KR20140009275A (ko) | 2010-12-09 | 2014-01-22 | 제넨테크, 인크. | 파클리탁셀 및 트라스투주맙-mcc-dm1에 의한 her2-양성 암의 치료 |
-
2016
- 2016-05-27 PT PT167301233T patent/PT3302551T/pt unknown
- 2016-05-27 WO PCT/US2016/034835 patent/WO2016196373A2/en active Application Filing
- 2016-05-27 PL PL16730123.3T patent/PL3302551T3/pl unknown
- 2016-05-27 DK DK16730123.3T patent/DK3302551T3/da active
- 2016-05-27 FI FIEP16730123.3T patent/FI3302551T3/fi active
- 2016-05-27 LT LTEPPCT/US2016/034835T patent/LT3302551T/lt unknown
- 2016-05-27 CN CN201680031816.8A patent/CN107614015A/zh active Pending
- 2016-05-27 EP EP16730123.3A patent/EP3302551B1/en active Active
- 2016-05-27 US US15/576,593 patent/US11406715B2/en active Active
- 2016-05-27 JP JP2017561971A patent/JP6822980B2/ja active Active
- 2016-05-27 RS RS20240909A patent/RS65871B1/sr unknown
-
2021
- 2021-01-07 JP JP2021001246A patent/JP7330217B2/ja active Active
-
2022
- 2022-07-19 US US17/813,466 patent/US20220354961A1/en active Pending
-
2023
- 2023-04-11 JP JP2023064033A patent/JP2023100635A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP3302551B1 (en) | 2024-06-26 |
| FI3302551T3 (fi) | 2024-08-27 |
| JP6822980B2 (ja) | 2021-01-27 |
| PL3302551T3 (pl) | 2024-09-30 |
| JP2018516920A (ja) | 2018-06-28 |
| US20220354961A1 (en) | 2022-11-10 |
| US20190030181A1 (en) | 2019-01-31 |
| US11406715B2 (en) | 2022-08-09 |
| WO2016196373A8 (en) | 2017-11-30 |
| EP3302551A2 (en) | 2018-04-11 |
| JP7330217B2 (ja) | 2023-08-21 |
| JP2021073203A (ja) | 2021-05-13 |
| DK3302551T3 (da) | 2024-08-26 |
| PT3302551T (pt) | 2024-08-21 |
| WO2016196373A2 (en) | 2016-12-08 |
| JP2023100635A (ja) | 2023-07-19 |
| WO2016196373A3 (en) | 2017-02-02 |
| RS65871B1 (sr) | 2024-09-30 |
| CN107614015A (zh) | 2018-01-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL275663A (en) | Cancer treatment methods | |
| IL269026A (en) | Tumor treatment methods | |
| HK1258098A1 (zh) | 治療癌症的方法 | |
| HK1251409A1 (zh) | 治療癌症的方法 | |
| IL263925A (en) | Methods of treating ovarian cancer | |
| HK1252272A1 (zh) | 使用抗ox40抗體治療癌症的方法 | |
| ZA201804227B (en) | Methods of treating cancer | |
| IL262342A (en) | Cancer treatment methods | |
| IL264443A (en) | Prostate cancer treatment methods | |
| IL266324A (en) | Treatment of her2-positive breast cancer | |
| IL266917A (en) | Methods for treating prolactin receptor-positive breast cancer | |
| IL271934A (en) | Methods for treating tumor metastases | |
| ZA201908539B (en) | Method of treatment of cancer | |
| SG11202010793UA (en) | Methods of treating cancer | |
| IL277981A (en) | Cancer treatment methods | |
| SG11202005163PA (en) | Methods of treating cancer | |
| IL281600A (en) | Methods of treating cancer | |
| PL3302551T3 (pl) | Sposoby leczenia HER2-dodatniego, wcześniej nieleczonego przerzutowego raka sutka | |
| IL272379A (en) | Methods for treating cancer using SETDS inhibition | |
| IL269123A (en) | Methods of treating cancer | |
| EP3442555A4 (en) | METHODS OF TREATING BREAST CANCER | |
| EP3389670A4 (en) | METHODS OF TREATING BREAST CANCER | |
| GB201510197D0 (en) | Method of treating ovarian cancer | |
| GB201702139D0 (en) | Methods of cancer treatment |